~~<i id='C541FE26E1'><strike id='C541FE26E1'><tt id='C541FE26E1'><pre id='C541FE26E1'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

comprehensive

author：knowledge 2025-10-01 02:12:18 - browse：6

A European regulatory panel has recommended against approval of a lung cancer drug made by Mirati Therapeutics, the company said Friday.

Mirati said it will appeal the negative opinion of the drug, called Krazati, issued by a committee of the European Medicines Agency that met this week. But for now, the adverse decision is likely to be adopted by European regulators and prevent the company from marketing the pill in Europe.

Krazati works by blocking a specific type of KRAS alteration called G12C, found in approximately 13% of lung tumors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Why are elite athletes different? Take a look at their microbes

focus

knowledge

hotspot

knowledge

explore

focus

ObesityexpertsJamyArd(left)andRobertLustigspeakatapanelduringthe2023STATBreakthroughSummit.SarahGonz

WSS

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

Gene therapy has helped boys walk. Can scientists keep it that way?

Elevance, SCAN deals highlight health insurer acquisition scrutiny

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

Why drug prescriptions should include diagnoses

Obesity experts on risks of Wegovy, Ozempic weight loss drugs

focus

comprehensive

focus

Peter Hotez and the public health issue of online harassment

Disclosing genetic information: not as worrisome as once feared

Anesthesiologist group: stop taking Ozempic before surgery

Obamacare plans could cover weight loss drugs

Hepatitis C has a cure — but many Americans still lack access to it

FDA warns medical device makers about rise in fabricated data

After affirmative action ruling, medical educators look to 'holistic review'

#NeedHerScience: shining a light on gender disparities in medicine

In age of alternative facts, a scholarly course on calling out crap

New study raises questions about niacin and heart health

knowledge

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

Why drug prescriptions should include diagnoses

Surprise medical billing ban raises prices elsewhere

The story of mRNA: From a loose idea to a tool that may help curb Covid

FDA warns medical device makers about rise in fabricated data

CDC concerned about possible undetected monkeypox spread in U.K.

hotspot

knowledge

explore

focus